Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor
Kavain positively modulated γ-Aminobutyric acid type A (GABAA) receptor
InChi: InChI=1S/C26H25F3N8O/c27-26(28
C4H4O4/c1-3-9-19(10-4-1)11-7-8-16-22-17-14-21(15-18-22)20-12-5-2-6-13-20
4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide
RS 09 Catalog No.:M25681-C MDR-1339 (DWK-1339) is an orallyRS09 is a LPS peptide mimic serves as a candidate to be considered as a new class of TLR4 agonist adjuvant. RS09 increases antibody production in a vaccine setting. Product information CAS Number: 1449566 36 2 Molecular Weight: 691. 78 Formula: C31H49N9O9 Chemical Name: (2S) 2 [(2S) 2 [(2S) 2 [(2S) 2 {[(2S) 1 [(2S) 1 [(2S) 2 aminopropanoyl]pyrrolidine 2 carbonyl]pyrrolidin 2 yl]formamido} 3 (1H imidazol 5 yl)propanamido]propanamido] 4
US$ 17.95
US$ 455.00
US$ 129.47